Format

Send to

Choose Destination
Neurosci Lett. 2007 Jan 10;411(2):98-103. Epub 2006 Nov 15.

Metformin therapy in a transgenic mouse model of Huntington's disease.

Author information

1
Division of Pharmacology, The Ohio State University, 412 Riffe Building, 496 West 12th Avenue, Columbus, OH 43210, USA.

Abstract

Huntington's disease (HD) is a hereditary neurodegenerative disease that leads to striatal degeneration and a severe movement disorder. We used a transgenic mouse model of HD (the R6/2 line with approximately 150 glutamine repeats) to test a new therapy for this disease. We treated HD mice with metformin, a widely used anti-diabetes drug, in the drinking water (0, 2 or 5mg/ml) starting at 5 weeks of age. Metformin treatment significantly prolonged the survival time of male HD mice at the 2mg/ml dose (20.1% increase in lifespan) without affecting fasting blood glucose levels. This dose of metformin also decreased hind limb clasping time in 11-week-old mice. The higher dose did not prolong survival, and neither dose of metformin was effective in female HD mice. Collectively, our results suggest that metformin may be worth further investigation in additional HD models.

PMID:
17110029
DOI:
10.1016/j.neulet.2006.10.039
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center